These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37260974)

  • 1. Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer.
    Xu C; Pei D; Liu Y; Guo J; Liu N; Wang Q; Yu Y; Kang Z
    Front Oncol; 2023; 13():918324. PubMed ID: 37260974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study.
    Song L; Xu C; Zhang T; Chen S; Shi Z; Hu S; Cheng B; Tong H; Wei G; Li X
    Front Surg; 2022; 9():934148. PubMed ID: 36111234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients Undergoing Surgery With Prostate Cancer: A Population-Based Study.
    Zhang Z; Zhanghuang C; Wang J; Mi T; Liu J; Tian X; Jin L; He D
    Front Public Health; 2022; 10():935521. PubMed ID: 35903379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis.
    Huang H; Li Z; Huang Z; Huang L; Liu W; Liu G; Mo Y
    Front Oncol; 2023; 13():1076997. PubMed ID: 37152061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cause-specific mortality of low and selective intermediate-risk prostate cancer patients with active surveillance or watchful waiting.
    Wu X; Lv D; Eftekhar M; Cai C; Zhao Z; Gu D; Liu Y
    Transl Androl Urol; 2021 Jan; 10(1):154-163. PubMed ID: 33532305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and verification of a nomogram to predict tumor-specific mortality risk in triple-negative breast cancer: a competing risk model based on the SEER cohort study.
    Li Z; Shi Y; Wu L; Zhang H; Xue J; Li W; Wang X; Zhang L; Wang Q; Duo L; Wang M; Wang G
    Gland Surg; 2022 Dec; 11(12):1961-1975. PubMed ID: 36654948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel risk prediction nomogram for early death in patients with resected synchronous multiple primary colorectal cancer based on the SEER database.
    Zhang X; Zhao L; Hu Y; Deng K; Ren W
    Int J Colorectal Dis; 2023 May; 38(1):130. PubMed ID: 37191907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive Risk Model Nomogram to Predict Prognosis in Patients Aged Over 65 Years with nonmetastatic Cervical Cancer: A SEER Population-Based Study.
    Jiao S; Guo L; Da F; Gao Q; Ren Z; Wang J; Fu Q; Liu J
    Technol Cancer Res Treat; 2023; 22():15330338231164191. PubMed ID: 37078156
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel nomogram predicting cancer-specific survival in small cell lung cancer patients with brain metastasis.
    Rong YT; Zhu YC; Wu Y
    Transl Cancer Res; 2022 Dec; 11(12):4289-4302. PubMed ID: 36644187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of Nomograms to Predict Cancer-Specific Survival and Overall Survival in Elderly Patients With Prostate Cancer: A Population-Based Study.
    Zhang Z; Zhanghuang C; Wang J; Tian X; Wu X; Li M; Mi T; Liu J; Jin L; Li M; He D
    Front Oncol; 2022; 12():918780. PubMed ID: 35814387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
    Dess RT; Suresh K; Zelefsky MJ; Freedland SJ; Mahal BA; Cooperberg MR; Davis BJ; Horwitz EM; Terris MK; Amling CL; Aronson WJ; Kane CJ; Jackson WC; Hearn JWD; Deville C; DeWeese TL; Greco S; McNutt TR; Song DY; Sun Y; Mehra R; Kaffenberger SD; Morgan TM; Nguyen PL; Feng FY; Sharma V; Tran PT; Stish BJ; Pisansky TM; Zaorsky NG; Moraes FY; Berlin A; Finelli A; Fossati N; Gandaglia G; Briganti A; Carroll PR; Karnes RJ; Kattan MW; Schipper MJ; Spratt DE
    JAMA Oncol; 2020 Dec; 6(12):1912-1920. PubMed ID: 33090219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study.
    Song C; Yu D; Wang Y; Wang Q; Guo Z; Huang J; Li S; Hu W
    Front Oncol; 2020; 10():515606. PubMed ID: 33194578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram for the prediction of lymph node metastasis and survival outcomes in rectal neuroendocrine tumour patients undergoing resection.
    Chen Q; Chen J; Deng Y; Zhang Y; Huang Z; Zhao H; Cai J
    J Gastrointest Oncol; 2022 Feb; 13(1):171-184. PubMed ID: 35284104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort.
    Wang Q; Wang Y; Wang X; Nakamura Y; Hydbring P; Yamauchi Y; Zhao X; Cao M
    Transl Lung Cancer Res; 2022 Aug; 11(8):1678-1691. PubMed ID: 36090634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.
    Liang Z; Zhang E; Duan L; Weygant N; An G; Hu B; Yao J
    Technol Cancer Res Treat; 2022; 21():15330338211068960. PubMed ID: 35179409
    [No Abstract]   [Full Text] [Related]  

  • 17. Nomogram Predicts Overall Survival in Patients With Stage IV Thyroid Cancer (TC): A Population-Based Analysis From the SEER Database.
    Yang T; Hu T; Zhao M; He Q
    Front Oncol; 2022; 12():919740. PubMed ID: 35898883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis.
    Jin S; Liu H; Yang J; Zhou J; Peng D; Liu X; Zhang H; Zeng Z; Ye YN
    Front Endocrinol (Lausanne); 2022; 13():882279. PubMed ID: 36176465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with metastatic clear cell renal carcinoma: A study based on SEER database.
    Huang G; Liao J; Cai S; Chen Z; Qin X; Ba L; Rao J; Zhong W; Lin Y; Liang Y; Wei L; Li J; Deng K; Li X; Guo Z; Wang L; Zhuo Y
    Front Oncol; 2022; 12():949058. PubMed ID: 36237316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.
    Wu X; Yu W; Petersen RH; Sheng H; Wang Y; Lv W; Hu J
    BMC Cancer; 2020 May; 20(1):429. PubMed ID: 32416716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.